Free Trial

VistaGen Therapeutics (VTGN) Stock Price, News & Analysis

VistaGen Therapeutics logo
$3.23 +0.05 (+1.57%)
As of 03:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About VistaGen Therapeutics Stock (NASDAQ:VTGN)

Key Stats

Today's Range
$3.14
$3.32
50-Day Range
$1.96
$3.40
52-Week Range
$1.90
$3.59
Volume
219,953 shs
Average Volume
257,714 shs
Market Capitalization
$99.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Buy

Company Overview

VistaGen Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

VTGN MarketRank™: 

VistaGen Therapeutics scored higher than 26% of companies evaluated by MarketBeat, and ranked 860th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for VistaGen Therapeutics are expected to grow in the coming year, from ($1.77) to ($1.74) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of VistaGen Therapeutics is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of VistaGen Therapeutics is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    VistaGen Therapeutics has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about VistaGen Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.72% of the float of VistaGen Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    VistaGen Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in VistaGen Therapeutics has recently decreased by 5.00%, indicating that investor sentiment is improving.
  • Dividend Yield

    VistaGen Therapeutics does not currently pay a dividend.

  • Dividend Growth

    VistaGen Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.72% of the float of VistaGen Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    VistaGen Therapeutics has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in VistaGen Therapeutics has recently decreased by 5.00%, indicating that investor sentiment is improving.
  • News Sentiment

    VistaGen Therapeutics has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for VistaGen Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    Only 5 people have searched for VTGN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, VistaGen Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.85% of the stock of VistaGen Therapeutics is held by insiders.

  • Percentage Held by Institutions

    78.39% of the stock of VistaGen Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about VistaGen Therapeutics' insider trading history.
Receive VTGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for VistaGen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VTGN Stock News Headlines

When the levee breaks
The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.tc pixel
Vistagen (VTGN) Q1 R&D Expense Jumps 54%
See More Headlines

VTGN Stock Analysis - Frequently Asked Questions

VistaGen Therapeutics' stock was trading at $2.95 on January 1st, 2025. Since then, VTGN shares have increased by 9.2% and is now trading at $3.22.

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) posted its quarterly earnings data on Thursday, August, 7th. The company reported ($0.47) earnings per share for the quarter, meeting the consensus estimate of ($0.47). The business earned $0.24 million during the quarter, compared to the consensus estimate of $0.22 million. VistaGen Therapeutics had a negative trailing twelve-month return on equity of 74.06% and a negative net margin of 6,777.08%.
Read the conference call transcript
.

VistaGen Therapeutics's stock reverse split before market open on Wednesday, June 7th 2023.The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Top institutional shareholders of VistaGen Therapeutics include Stempoint Capital LP (7.87%), AdvisorShares Investments LLC (0.68%), Jane Street Group LLC (0.31%) and Persistent Asset Partners Ltd (0.28%).
View institutional ownership trends
.

Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that VistaGen Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

Last Earnings
8/07/2025
Today
8/28/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VTGN
CIK
1411685
Employees
40
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.78)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$51.42 million
Net Margins
-6,777.08%
Pretax Margin
-8,633.59%
Return on Equity
-74.06%
Return on Assets
-64.10%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.98
Quick Ratio
5.98

Sales & Book Value

Annual Sales
$646 thousand
Price / Sales
156.72
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.85 per share
Price / Book
1.78

Miscellaneous

Outstanding Shares
30,680,000
Free Float
29,806,000
Market Cap
$101.24 million
Optionable
Optionable
Beta
0.40

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:VTGN) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners